ARCHIMED completes acquisition of Standard BioTools' microfluidics business
LAB•ARCHIMED completed its acquisition of Standard BioTools' microfluidics business. The business will operate independently as Biomark Scientific, with a dedicated leadership team to be installed over the coming months.
1. Business to operate independently
The genomic tools business will operate independently as Biomark Scientific, with plans to expand internationally and invest in innovation. A dedicated leadership team is expected to be installed over the coming months as the business establishes standalone operations.
2. Acquisition financing
The acquisition was completed through MED IV, which closed at €1.5 billion in September and was three times oversubscribed.
